Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29624582 | 0.85 | CA12 (0.49) | LMNAMAPTPOLBHSD17B10GAA | |
| SCHEMBL16327448 | 0.85 | LMNA (0.61) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL13864994 | 0.83 | KDM4E (0.41) | LMNAMAPTPOLBPKMGAA | |
| SCHEMBL18371643 | 0.82 | CYP19A1 (0.38) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL13721436 | 0.80 | LMNA (0.51) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL20212072 | 0.79 | LMNA (0.55) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL7523552 | 0.78 | ELANE (0.61) | LMNAMAPTPOLBPKMELANE | |
| SCHEMBL8049735 | 0.77 | ALDH1A1 (0.43) | LMNAMAPTPKMALDH1A1KDM4E | |
| SCHEMBL3846192 | 0.77 | GRM5 (0.39) | ALDH1A1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL6949563 | 0.76 | FFAR1 (0.65) | LMNAMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025604-A2 | DEVELOPMENT OF AN ENZYME-INHIBITOR REACTION USING CELLULAR RETINOIC ACID BINDING PROTEIN II FOR ONE-POT MEGAMOLECULE ASSEMBLY | NORTHWESTERN UNIVERSITY (US) | 2024-02-01 | — | — | WO | disclosed |
| US-6818666-B2 | FOR EXAMPLE, METHYL 4-(5,5,8,8,-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2 -NAPHTHYLSULPHANYLETHYNYL)BENZOATE; USE IN HUMAN OR VETERINARY MEDICINE OR COSMETIC COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2004-11-16 | — | — | US | disclosed |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | disclosed |
| US-6441010-B2 | USEFUL AS COSMETIC FOR HAIR AND BODY HYGIENE, AND FOR TREATMENT OF DERMATOLOGICAL COMPLAINTS, WITH AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT OF RHEUMATIC OR RESPIRATORY TYPE, CARDIVASCULAR AND OPTHALMOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-08-27 | — | — | US | disclosed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | disclosed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | TYR, KRT18, SCO2 | LMNA 966/4885MAPT 3343/4885POLB 1882/4885 |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | TYR, AHR, CYP2C19 | LMNA 1784/4885MAPT 1280/4885POLB 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.